Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypercholinergic activity in LRRK2 Parkinson's disease.

The Lancet. Neurology - 1 Apr 2018

Bohnen Nicolaas I, Albin Roger L

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Parkinson Disease
Share to Cross-Sectional Studies
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 29456160
DOI: 10.1016/S1474-4422(18)30073-5
PMCID: PMC5858987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypercholinergic activity in LRRK2 Parkinson's disease.PMID 29456160Read ↗

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

LRRK2 inhibitor progresses for Parkinson disease.Semantic proximity Read ↗

LRRK2-targeted Parkinson disease drug advances into phase IIISemantic proximity Read ↗

Screening for chemical modulators for LRRK2.Semantic proximity Read ↗

A step forward for LRRK2 inhibitors in Parkinson's disease.Semantic proximity Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

Lysosomal TPC2 channels disrupt Ca2+ entry and dopaminergic function in models of LRRK2-Parkinson's disease.Semantic proximity Read ↗

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.Semantic proximity Read ↗

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.Semantic proximity Read ↗

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.Semantic proximity Read ↗

Higher urate in LRRK2 mutation carriers resistant to Parkinson diseaseSemantic proximity Read ↗

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.